CLL Video Channel
Explore the latest insights and summaries from experts in CLL.
Recommended for You
Loading...
Trending Videos This Week
Loading...
Treatment Landscape
Massachusetts General Hospital Cancer Center
Practice-Changing Updates in Indolent B-Cell Lymphomas
FEATURING
Jake Soumerai
- 469 views
- June 5, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and EHA
FEATURING
Kerry Rogers,
Jennifer Woyach
- 311 views
- June 21, 2024
- 1
Cleveland Clinic Taussig Cancer Institute
R/R CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors
FEATURING
Brian Hill
- 53 views
- June 25, 2024
City of Hope
Venetoclax vs. BTKis in CLL Treatment
FEATURING
Alexey Danilov
- 255 views
- June 28, 2024
- 1
Total Health
Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL, MM, and CLL
FEATURING
Marcello Maria Rotta
- 240 views
- July 8, 2024
SOHO Brazil 2024
Single vs. Multiple Agents in 2L Therapy for CLL
FEATURING
Jan Burger
- 351 views
- July 11, 2024
- 2
SOHO Brazil 2024
3L in CLL: The Best Options in a Patient Double-Refractory to Covalent BTKi and to BCL-2 Inhibitor
FEATURING
Jan Burger
- 502 views
- July 11, 2024
- 1
SOHO Brazil 2024
1L Therapy in CLL: What Are the Best Options?
FEATURING
Jan Burger
- 845 views
- July 11, 2024
- 2
UChicago Medicine
The Next Frontier of Targeted Therapy in Lymphoma
FEATURING
Kami Maddocks
- 238 views
- July 22, 2024
UChicago Medicine
Improving Lymphoma Outcomes: Optimizing Trial Design, Using Surrogate Endpoints, and Incorporating Guidelines
FEATURING
Andrew Zelenetz
- 106 views
- July 22, 2024
- 1
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Current Options for Finite-Duration Therapy With BTKis in CLL
FEATURING
Ahmad Ibrahim
- 150 views
- August 13, 2024
Nicole Lamanna
Sequencing Therapies in CLL: The Importance of First-Line Treatment Choice
- 260 views
- August 27, 2024
- 3
MyCancerHaven
Experts Discuss Recent Developments in CLL
FEATURING
Ravi Vij,
Dahlia Sano
- 70 views
- August 30, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
CLL Case Discussion: First Line Treatment Strategies
FEATURING
Damla Ortaboz
- 61 views
- September 6, 2024
Farrukh Awan
Clinical & Non-Clinical Benefits of Fixed-Duration Venetoclax Treatment in CLL
- 40 views
- September 5, 2024
Yale Cancer Center
Caring for Patients With Lymphoma: Using Guidelines to Improve Quality of Care
FEATURING
Scott Huntington,
Eric Winer
- 77 views
- September 11, 2024
Cleveland Clinic Taussig Cancer Institute
Updates in CLL From ASH 2023
FEATURING
Allison Winter
- 88 views
- October 22, 2024
City of Hope
Incorporating Pirtobrutinib and CAR-T Therapy Into CLL Practice
FEATURING
Alexey Danilov
- 43 views
- November 12, 2024
Danielle Brander
Choosing BTKi or BCL2i or Combination Therapy for 1L CLL
- 314 views
- November 18, 2024
- 3
University of Colorado Division of Hematology
Summary and Practice Impacts of Recent Updates in B-Cell Lymphomas
FEATURING
Manali Kamdar
- 252 views
- April 8, 2024
- 1
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignancies
FEATURING
Ruemu Birhiray
- 914 views
- April 16, 2024
- 5
Indy Hematology Review
Treatment Considerations for Initial Therapy of CLL
FEATURING
Peter Hillmen
- 230 views
- April 18, 2024
- 3
Indy Hematology Review
CLL: Evaluating and Therapeutic Approaches for the Management of the R/R Patient
FEATURING
Jennifer Woyach
- 295 views
- April 23, 2024
- 1
Yale Cancer Center
Yale Cancer Center Updates on B-Cell Lymphomas: Exploring MCL, DLBCL, FL, and CLL/SLL
FEATURING
Shalin Kothari
- 132 views
- May 13, 2024
Yale Cancer Center
Case-Based Discussions in Lymphoma: 1L MCL, CD30+ T-Cell, and R/R CLL
- 94 views
- May 14, 2024
MyCancerHaven
Conversation With Cancer Experts: Current Treatment of R/R CLL
FEATURING
Ravi Vij,
Marc Hoffmann
- 22 views
- November 26, 2024
MyCancerHaven
Conversation With Cancer Experts: Treatment of Double Refractory CLL
FEATURING
Ravi Vij,
Ryan Jacobs
- 31 views
- November 26, 2024
City of Hope
CLL Treatment Sequencing: The Importance of First Choice
FEATURING
Steven Rosen
- 317 views
- July 3, 2024
Moffitt Cancer Center
Optimal Management of Patients With CLL in 2024: Interactive Cases Discussion
FEATURING
Javier Pinilla-Ibarz
- 155 views
- March 4, 2024
City of Hope
Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Targeted Strategies
FEATURING
Idoroenyi Amanam
- 208 views
- March 11, 2024
- 1
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Practical Updates on Advances in CLL and MCL
FEATURING
Elise Chong
- 269 views
- March 13, 2024
- 1
Scripps Health
Updates in CLL: Treatment for BTKi-Refractory and BTKi/BCL-2i-Refractory Disease
FEATURING
Susan O'Brien
- 243 views
- March 18, 2024
SOHO Highlights: State of the Art and Next Questions
CLL: State of the Art and Next Questions
FEATURING
Nitin Jain
- 259 views
- March 25, 2024
- 1
Nicole Lamanna
Pirtobrutinib in CLL: Current and Potential Utility in the Treatment Landscape
- 88 views
- December 3, 2024
Fred Hutchinson Cancer Center
Current Guideline-Informed Treatment of CLL
FEATURING
Chaitra Ujjani
- 47 views
- December 13, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Acalabrutinib, Venetoclax, Obinutuzumab in a 1L CLL Enriched for High-Risk Disease
FEATURING
Matthew Davids
- 5 views
- December 13, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ibrutinib or Acalabrutinib in CLL - Impact of Dose Reduction on Therapy Duration
FEATURING
Mazyar Shadman
- 25 views
- December 17, 2024
Therapeutic Agents
Massachusetts General Hospital Cancer Center
Practice-Changing Updates in Indolent B-Cell Lymphomas
FEATURING
Jake Soumerai
- 469 views
- June 5, 2024
- 1
Cleveland Clinic Taussig Cancer Institute
R/R CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors
FEATURING
Brian Hill
- 53 views
- June 25, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Advantages of Using Venetoclax-Based Therapy in High-Risk CLL
FEATURING
Catherine Coombs
- 87 views
- June 28, 2024
- 1
City of Hope
Venetoclax vs. BTKis in CLL Treatment
FEATURING
Alexey Danilov
- 255 views
- June 28, 2024
- 1
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Sonrotoclax + Zanubrutinib in R/R CLL/SLL
FEATURING
Stephen S. Opat
- 53 views
- July 3, 2024
Saad Kenderian
Liso-Cel in CLL: Summary of FDA Approval and Guidance on Toxicity Management
- 128 views
- July 8, 2024
- 1
SOHO Brazil 2024
3L in CLL: The Best Options in a Patient Double-Refractory to Covalent BTKi and to BCL-2 Inhibitor
FEATURING
Jan Burger
- 502 views
- July 11, 2024
- 1
UChicago Medicine
The Next Frontier of Targeted Therapy in Lymphoma
FEATURING
Kami Maddocks
- 238 views
- July 22, 2024
UChicago Medicine
Exploring the Value of PI3K in Lymphoma Treatment
FEATURING
Changchun Deng
- 18 views
- July 22, 2024
UChicago Medicine
Targeting BTK in B-Cell NHL: Pros and Cons of Inhibitors and Degraders
FEATURING
Adam Kittai
- 48 views
- July 22, 2024
- 1
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Venetoclax + Ibrutinib as 1L Treatment in Patients With CLL: Meta-Analysis of RCTs
FEATURING
Ahmet Sarici
- 31 views
- August 15, 2024
MyCancerHaven
Experts Discuss Recent Developments in CLL
FEATURING
Ravi Vij,
Dahlia Sano
- 70 views
- August 30, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in CLL: Continuous or Finite Duration Therapy
FEATURING
Nitin Jain
- 165 views
- October 6, 2024
NYU Langone
Long-Term Efficacy of Ibrutinib in CLL
FEATURING
Marc Braunstein
- 78 views
- October 6, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Novel Agents in the Treatment of R/R CLL
FEATURING
Nitin Jain
- 44 views
- October 9, 2024
Cleveland Clinic Taussig Cancer Institute
Updates in CLL From ASH 2023
FEATURING
Allison Winter
- 88 views
- October 22, 2024
Northwestern Medicine Oncology and Hematology
Pirtobrutinib in R/R CLL: Most Recent BRUIN Trial Results
FEATURING
Shuo Ma
- 38 views
- October 29, 2024
City of Hope
Incorporating Pirtobrutinib and CAR-T Therapy Into CLL Practice
FEATURING
Alexey Danilov
- 43 views
- November 12, 2024
University of Colorado Division of Hematology
Summary and Practice Impacts of Recent Updates in B-Cell Lymphomas
FEATURING
Manali Kamdar
- 252 views
- April 8, 2024
- 1
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignancies
FEATURING
Ruemu Birhiray
- 914 views
- April 16, 2024
- 5
Constantine Tam
R/R CLL: A Matching-Adjusted Indirect Comparison of Zanubrutinib vs. Acalabrutinib
- 315 views
- April 22, 2024
Indy Hematology Review
CLL: Evaluating and Therapeutic Approaches for the Management of the R/R Patient
FEATURING
Jennifer Woyach
- 295 views
- April 23, 2024
- 1
MyCancerHaven
CLL and MCL: Experts Discuss the Use of Pirtobrutinib
FEATURING
Ravi Vij,
Geoffrey Shouse
- 240 views
- May 7, 2024
- 2
Yale Cancer Center
Yale Cancer Center Updates on B-Cell Lymphomas: Exploring MCL, DLBCL, FL, and CLL/SLL
FEATURING
Shalin Kothari
- 132 views
- May 13, 2024
Manfred Welslau
Ibrutinib for CLL: The Importance of Adherence in Optimizing Efficacy
- 246 views
- May 21, 2024
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Practical Updates on Advances in CLL and MCL
FEATURING
Elise Chong
- 269 views
- March 13, 2024
- 1
Scripps Health
Updates in CLL: Treatment for BTKi-Refractory and BTKi/BCL-2i-Refractory Disease
FEATURING
Susan O'Brien
- 243 views
- March 18, 2024
Fred Hutchinson Cancer Center
FDA Approval of Liso-Cel in R/R CLL: What You Need to Know
FEATURING
Mazyar Shadman
- 149 views
- March 26, 2024
Lydia Scarfò
Managing Cardiotoxicities in BTKi Treatment for CLL: Atrial Fibrillation and Atrial Flutter
- 87 views
- October 15, 2024
Avirup Guha
Managing Cardiotoxicities in TKI Therapy for CLL: Atrial Fibrillation and Atrial Flutter
- 80 views
- October 23, 2024
Nicole Lamanna
Pirtobrutinib in CLL: Current and Potential Utility in the Treatment Landscape
- 88 views
- December 3, 2024
Fox Chase Cancer Center
Pirtobrutinib in R/R B-Cell Malignancies: Newest Data From the BRUIN Trial
FEATURING
Shazia Nakhoda
- 16 views
- December 13, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Acalabrutinib, Venetoclax, Obinutuzumab in a 1L CLL Enriched for High-Risk Disease
FEATURING
Matthew Davids
- 5 views
- December 13, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ibrutinib or Acalabrutinib in CLL - Impact of Dose Reduction on Therapy Duration
FEATURING
Mazyar Shadman
- 25 views
- December 17, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Zanubrutinib in Acalabrutinib-Intolerant Patients With B-Cell Malignancies
FEATURING
Mazyar Shadman
- 2 views
- December 18, 2024
Diagnostics & Biomarkers
UChicago Medicine
Debates in CLL: Measuring MRD is NOT the SOC
FEATURING
Jacob Soumerai
- 206 views
- July 22, 2024
- 2
UChicago Medicine
Debates in CLL: MRD Measurement in Fixed Duration Venetoclax-Based Therapy is SOC
FEATURING
Joanna Rhodes
- 74 views
- July 22, 2024
- 2
ecancer
EHA 2024 Insights: Only Certain TP53 Mutations are Prognostic for PFS and OS in CLL
FEATURING
Consuelo Bertossi
- 55 views
- July 23, 2024
- 1
MyCancerHaven
Evolving Concepts in CLL: Incorporating MRD
FEATURING
Ravi Vij,
Danielle Brander
- 149 views
- August 30, 2024
Insights from 2023 ASH Annual Meeting
Zanubrutinib in 1L CLL: A Biomarker Analysis From the Phase 3 SEQUOIA Study
FEATURING
Paolo Ghia
- 115 views
- March 27, 2024
Disease Overview
Yale Cancer Center
Caring for Patients With Lymphoma: Using Guidelines to Improve Quality of Care
FEATURING
Scott Huntington,
Eric Winer
- 77 views
- September 11, 2024
Masonic Cancer Center, University of Minnesota
Blood Cancers Basics
FEATURING
Zohar Sachs
- 27 views
- October 7, 2024
Brian Koffman
Supporting Patients With CLL: Highlighting the Importance of Community
- 26 views
- November 1, 2024
Case Studies
XV Eurasian Hematology-Oncology Congress - EHOC 2024
CLL Case Discussion: First Line Treatment Strategies
FEATURING
Damla Ortaboz
- 61 views
- September 6, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
MPN Case Discussion: ET With Coincindent CLL
FEATURING
Giuseppe Saglio
- 10 views
- September 27, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
CLL Case: Acquired Del(17p) at Relapse
FEATURING
Melis Dila Özer Çerme
- 8 views
- October 15, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
CLL Case Discussion: Diagnosis and Managment of Richter Syndrome
FEATURING
Mohammed Kamil Al Qayyim
- 9 views
- October 15, 2024
Yale Cancer Center
Case-Based Discussions in Lymphoma: 1L MCL, CD30+ T-Cell, and R/R CLL
- 94 views
- May 14, 2024
Moffitt Cancer Center
Optimal Management of Patients With CLL in 2024: Interactive Cases Discussion
FEATURING
Javier Pinilla-Ibarz
- 155 views
- March 4, 2024